Medikamentöse Therapie der akuten Herzinsuffizienz und des infarktbedingten kardiogenen Schocks

Abstract

Acute heart failure, especially cardiogenic shock, is still correlated with a poor prognosis. Although systemic inflammation and multi organ dysfunction as well as multi organ failure are of high predictive value, drug therapy in acute heart failure is predominantly based on the concept of hemodynamic stabilization directed to myocardial pre- and afterload and contractility. Under hemodynamic stable conditions diuretics and vasodilators are recommended, while in case of hemodynamic instability vasopressors and inotropic drugs are preferred therapeutic options. All drug treatment strategies in acute heart failure – in contrast to chronic heart failure – are characterized by little evidence.

• Literatur

• 1 Cotter G, Moshkovitz Y, Kaluski E et al. The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Fail 2003; 5: 443-451
• 2 Prondzinsky R, Lemm H, Swyter M et al. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 2010; 38: 152-160
• 3 Dietz S, Werdan K. Neue medikamentöse Therapieansätze bei akuter Herzinsuffizienz. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2013: 220-232
• 4 Werdan K, Ruß M, Buerke M. German Cardiac Society, German Society of Intensive Care and Emergency Medicine, German Society for Thoracic and Cardiovascular Surgery, (Austrian Society of Internal and General Intensive Care Medicine, German Interdisciplinary Association of Intensive Care and Emergency Medicine, Austrian Society of Cardiology, German Society of Anaesthesiology and Intensive Care Medicine, German Society of Preventive Medicine and Rehabilitation et al. Cardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment: a German-Austrian S3 Guideline. Dtsch Arztebl Int 2012; 109: 343-351
• 5 McMurray JJ, Adamopoulos S, Anker SD. ESC Committee for Practice Guidelines et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847 ; Erratum in: Eur Heart J 2013; 34: 158
• 6 Rex S, Marx G. Therapie der akuten Herzinsuffizienz – Treatment of acute heart failure. Anästh Intensivmed 2012; 53: 610-631
• 7 Follath F, Yilmaz MB, Delgado JF et al. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med 2011; 37: 619-626
• 8 Unverzagt S, Wachsmuth L, Hirsch K et al. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev 2014; 1 CD009669
• 9 Russ MA, Prondzinsky R, Christoph A et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 2007; 35: 2732-2739
• 10 Teerlink JR, Cotter G, Davison BA. (RELAX-AHF) Investigators et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. RELAXin in Acute Heart Failure. Lancet 2013; 381: 29-39